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ABSTRACT

Disclosed herein are methods and materials for promoting
neurogenesis of endogenous and transplanted stem cells.
Specifically exemplified herein are methods that comprise
transplanting neural stem cells in conjunction with a regimen
of ( +)phenserine treatment.
6 Claims, 7 Drawing Sheets
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METHOD OF BIASING IMPLANTED HUMAN
NEURAL STEM CELLS AWAY FROM
DIFFERENTIATION INTO GLIAL CELLS BY
(+)PHENSERINE TO MODULATE THE
CONCENTRATION OF SOLUBLE ~APP IN
TISSUE OR CSF

human-specific astroglial cells in the (A) CAI, (B) CA2 and
(C) dentate gyrus, measured bilaterally on four to six alternate
sections for each mouse. U p<0.01 indicates a significant
difference within saline treated group (Student's unpaired
t-test); (D) Correlation of APP protein levels with number of
GFAP+/Brdu+ cells in the hippocampus of 6-7 months old
APP23 mice that received saline only. Each point corresponds to average APP protein levels and number of GFAP+/
Brdu+ cells in the CAI, CA2 and dentate gyrus regions of
each individual mouse. (Linear regression r=0.47; p<0.05).
FIG. 5. Differentiation of HNSCs into neuronal cells in
vivo after treatment with either saline or (+)-phenserine (25
mg/kg). (a-d) Representative fluorescent immunohistochemical images in the CAI hippocampal region of 6-7
months old APP23 and non-transgenic mice 6 weeks after
HNSCs transplantation. Sections were double-immunofluorescence stained with ~III-tubulin (green) and BrdU (red)
markers for neural cells and donor cells, respectively. All
nuclei were counterstained by DAPI (blue).
FIG. 6. Differentiation of HNSCs into neuronal cells in
vivo after treatment with either saline or (+)-phenserine (25
mg/kg). (a-d) Representative fluorescent immunohistochemical images in the CA2 hippocampal region of 6-7
months old APP23 and non-transgenic mice 6 weeks after
HNSCs transplantation. Sections were double-immunofluorescence stained with ~III-tubulin (green) and BrdU (red)
markers for neural cells and donor cells, respectively. All
nuclei were counterstained by DAPI (blue).
FIG. 7. Immunohistochemical analysis of transplanted
HNSC expressing immunoreactivity for neuronal marker
~III-tubulin and Brdu after 6 weeks differentiation in hippocampal and cortical regions of 6-7 months old APP23 and
non-transgenic mice that were treated with either saline or
phenserine (25 mg/kg). All values are expressed as
mean±S.E.M. (n=6-7 within each group), and were obtained
by averaging counts of immuno-reactive human-specific neuronal cells in the (A) CAI, (B) CA2, (C) dentate gyrus and (D)
motor and (E) sensory cortex, measured bilaterally on four to
six alternate sections for each mouse. *** p<0.0001; * p<0.05
indicates a significant difference from saline treated (Student's unpaired t-test).
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RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional
Patent application Ser. No. 60/704,319, filed Aug. I, 2005,
incorporated herein by reference.
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BACKGROUND
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Patients currently suffering from neurodegenerative conditions such as Alzheimer's and Parkinson's have limited
treatment options. Conventional drug therapy helps delay or
reduce the symptoms of disease but is unable to restore complete functionality of the brain or repair damaged tissue.
Through stem cell-based therapies, scientists aim to transplant cells in order to regenerate damaged tissue and restore
proper function. However, the inventors have realized that the
ability of implanted cells to migrate properly to a desired
locus and to differentiate into a desired cell type are fundamental and vital obstacles for implementing in cell transplantation therapy. The inventors have made important strides in
addressing such issues.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. (A) Relative protein levels of total sAPP (22Cl I)
and GFAP in the hippocampus of6-8 months oldAPP23 and
non-transgenic mice that were treated with either saline or
( +)-phenserine (25 mg/kg) respectively, for 2 weeks. **
p<0.01 and * p<0.05 indicates significantly different from
saline treated. t p<0.05 indicates significantly different
within saline treated group (Student's unpaired t-test). All
values are expressed as mean±S.E.M. from 3-4 independent
experiments. (B) Representative Western blots for Sapp and
GFAP from saline (s) and (+)-phenserine (p) treatedAPP23
and non-transgenic mice.
FIG. 2. Differentiation of HNSCs into astroglial cells in
vivo after treatment with either saline or ( +)-phenserine (25
mg/kg). (a-d) Representative fluorescent immunohistochemical images in the CAI hippocampal region of 6-7
months old APP23 and non-transgenic mice 6 weeks after
HNSCs transplantation. Sections were double-immunofluorescence stained with GFAP (green) and BrdU (red) markers
for astroglia cells and donor cells, respectively. All nuclei
were counterstained by DAPI (blue).
FIG. 3. Differentiation of HNSCs into astroglial cells in
vivo after treatment with either saline or ( +)-phenserine (25
mg/kg). (a-d) Representative fluorescent immunohistochemical images in the CA2 hippocampal region of 6-7
months old APP23 and non-transgenic mice 6 weeks after
HNSCs transplantation. Sections were double-immunofluorescence stained with GFAP (green) and BrdU (red) markers
for astroglia cells and donor cells, respectively. All nuclei
were counterstained by DAPI (blue).
FIG. 4. Immunohistochemical analysis of transplanted
HNSC expressing immunoreactivity for GFAP and Brdu after
6 weeks differentiation inhippocampal regions of 6-7 months
old APP23 and non-transgenic mice that were treated with
either saline or phenserine (25 mg/kg). All values are
expressed as mean±S.E.M. (n=6-7 within each group), and
were obtained by averaging counts of immunoreactive

20

25

30

35

40

DETAILED DESCRIPTION
45

50

55

60

65

In reviewing the detailed disclosure which follows, and the
specification more generally, it should be borne in mind that
all patents, patent applications, patent publications, technical
publications, scientific publications, and other references referenced herein are hereby incorporated by reference in this
application, in their entirety to the extent not inconsistent with
the teachings herein.
It is important to an understanding of the present invention
to note that all technical and scientific terms used herein,
unless defined herein, are intended to have the same meaning
as commonly understood by one of ordinary skill in the art.
The techniques employed herein are also those that are known
to one of ordinary skill in the art, unless stated otherwise. For
purposes of more clearly facilitating an understanding the
invention as disclosed and claimed herein, the following definitions are provided.
The administration of cholinesterase inhibitors such as
(-)Phenserine is believed to be useful in treating cognitive
disorders such as Alzheimers disease. The potential positive
effects of administering cholinesterase inhibitors is somewhat offset by undesired and potentially dangerous side
effects. The administration of cholinesterase inhibitors is
believed to increase acetylcholine levels in the brain, which is

US 9,095,573 B2

3

4

depleted in anAlzheimers brain, and therefore increase activity of the brain's cholinergic system. However, such inhibitors produce a toxicity caused by their inhibition of acetylcholinesterase, such as nausea, vomiting, dizziness, tremors,
bradycardia, inter alia. Some in the field have tried using an
enantiomer of ( - ) phenserine in an effort to avoid some of
these undesired side effects. For example, Greig et al., U.S.
Patent Pub. 2004/0024043 AND 2004/0138282 discuss use
of (+) phenserine which lacks cholinesterase activity, avoiding the side effects of the cholinesterase inhibitors. Grieg et
al. demonstrated that administration of ( +) phenserine dramatically reduces ~APP levels in the brain. It is believed that
this lowering of ~APP levels in the brain in turn results in
lowered A~ levels. A~ is believed to induce progressive neurodegenerative condition leading to loss of memory characterized by the appearance of senile plaques that are primarily
composed of an A~ and neurofibrillary tangle aggregates.
The focus of the Greig et al. studies is the dramatic reduction of A~, thus, one is lead to strive toward shutting down
~APP production as much as possible. The inventors postulate that controlling ~APP rather than shutting down ~APP
levels is what is critical in optimizing brain conditions to
prevent progression of Alzheimer's disease. Indeed, the
inventors surmise that the shutting down ~APP production is
counterproductive; it may put a patient in a transient
improved state, but it will ultimately lead to a worsened state
of progression of the disease. This is discussed further below.
The brain harbors stems cells which require signals to
migrate to an area of need. ~APP is a primary inducer of stem
cell migration in the brain. The inventors have found that a
high concentration of ~APP in the brain will bias differentiation of neural stem cells into astrocytes. Thus, one of the
potential pathological bases for the progression of Alzheimer's disease is the exhaustion of endogenous stem cell
reserves in Alzheimer's brains which are differentiated into
an over abundance of astrocytes as opposed to new neurons.
The inventors have also discovered that controlling ~APP
levels in the brain to optimal levels is also critical when
implementing cell transplantation strategies. As with endogenous sources of stems cells, transplanted stem cells will also
be biased to produce undesired glial producing cells, such as
astrocytes. Thus, in one embodiment, the invention pertains
to a method of transplanting human neural stem cells in the
brain in conjunction with a regimen of ( +)phenserine treatment. (+)Phenserine may be administered a week to several
weeks prior to cell transplantation, and/or a week to weeks
subsequent to cell transplantation. Though generating an
environment of the brain with reduced levels of ~APP is
desired for cell transplantation therapies, generating
extremely low levels of ~APP will inhibit cell mobilization
which is needed for implanted cells to migrate to their needed
location, grow and differentiate in the desired phenotype.
Accordingly, in a preferred embodiment, (+)phenserine is
administered in conjunction with human neural stem cell
transplantation according to a regimen (dosage amount and
frequency) such that the site of transplantation comprises an
average ~APP concentration of about 0.5 to about 40 nanograms of ~APP per milliliter of tissue or cerebrospinal fluid.
Preferably, the regimen is such that an average ~APP concentration of about 1 to 10 nanograms/ml is maintained over a
period of at least one day, two days, one week, two weeks, one
month, two months, three months, four months, five months,
six months or one year.
U.S. Patent Application Nos. 2003/0219898, 2003/
0148513, and 2003/0139410 are incorporated by reference to
the extent they are not inconsistent with the teachings herein.
The first two of these patent applications describe multiple

uses of increased potency cells obtained from the taught
methods, and in particular, the implantation of stem cells for
different therapeutic treatments of neurological trauma and
degenerative conditions. The third patent application is
directed to the use of certain compounds to stimulate proliferation and migration of stem cells. Those skilled in the art
will readily appreciate that the cells of the present invention
could be obtained, or their effectiveness enhanced, by combining with the teachings of the aforementioned patent applications, without undue experimentation. Human neural stem
cells may be derived from embryonic or adult allogenic or
autogenic sources and may be genetically engineered to be
biased to differentiate into a desired phenotype. See for
example, co-pending U.S. application Nos. 60/621,483,
60/621,902, and 60/621,901
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Modulation of Human Neural Stem Cell
Differentiation in APP23 Transgenic Mice by
Phenserine Treatment
Materials and Methods
Human Neural Stem Cell Cultures.
HNSCs originally isolated from 9 weeks old fetal cortical
tissue were purchased from Bio Whittaker (Walkersville,
Md.) and the cells were expanded and passaged in a serumfree culture medium, as described in detail previously (Brannen and Sugaya, 2000). Briefly, HNSCs were cultured in 20
ml serum-free supplemented growth medium consisting of
Ham's F12/DMEM (Gibco, Burlington, ON), EGF (20
ng/ml, R & D Systems), FGF (20 ng/ml, R & D Systems,
Minneapolis, Minn.), B27 (1 :50, Gibco ), heparin (5 µg/ml,
Sigma, St. Louis, Mo.) and antibiotic-antimycotic mixure
(1: 100, Gibco) at 3 7° C. in a 5% humidified incubation chamber (Brannen and Sugaya, 2000). Prior to transplantation,
HNSCs were incubated with 3 µM bromo-deoxyuridine
(BrdU, Sigma) for 48 hr to label cell nuclei to distinguish
them from the host cells.
Animals.
APP23 mice, expressing the 751-amino acid human amyloid-precursor protein (hAPP751) with the Swedish double
mutation (K670N, M671L) driven by the neuron-specific
murine Thy-I-promoter (Sturchler-Pierrat et al., 1997) were
received as a gift from Novartis Pharma Ltd., (Switzerland),
and employed to breed a colony of experimental animals by
backcrossing to C57 /BL6 mice. Mixed genotype groups were
housed in standard mouse cages with access to food and water
ad libitum, constant room temperature and humidity, during a
12/12 hr light/dark cycle. Genotypes were confirmed by PCR
(Calhoun et al., 1999). In all experiments wild-type littermates served as controls. All animal experimental procedures
were carried out in compliance with National Institutes
Health Guidelines for Care and Use of Laboratory Animals,
and approved by the Animal Research Committee (protocol
00-24) at the University of Central Florida.
( +)-Phenserine Treatment.
A total of 55 age and sex-matched APP23 (n=30) and
wild-type (n=25) mice (ages ranged from 4-7 months) were
administered with either (+)-phenserine (25 mg/kg/day, i.p.)
or 0.9% saline (control) for 14 consecutive days. Animals
were subsequently divided into two groups that were either
sacrificed following 14 days treatment (n= 17 APP23 and
n=13 wild-type, respectively) or received transplantation of
HSNC into the lateral ventricle (n=13 APP23 mice and n=12
wild-type, respectively). (+)-Phenserine or saline injection
was continued once a day for 1 week after a 2-day recovery
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from transplantation surgery. All animals were sacrificed
within 12 hrs of receiving the final dose of ( +)-phenserine or
0.9% saline by an overdose of a 1: 1 mixture ofKetamine (100
mg/kg) and Xylazine (20 mg/kg), and transcardially perfused
with phosphate buffer (PBS). Brains were removed, dissected
into the hippocampus and cortex, and tissue samples were
maintained on dry ice and stored at -80° C. until Western
blotting and PCR experiments were performed. For the group
of transplanted animals, these were transcardially perfused
with PBS and 4% paraformaldehyde (pH 7.4). Brains were
removed and post-fixed for 8-12 h in 4% paraformaldehyde,
and cryoprotected in 20% sucrose-PBS overnight. The brains
were subsequently cut on a cryostat (20 µm coronal sections)
and kept in PBS at 4 ° C. for fluorescent immunohistochemical analysis.
Animal Surgery and Transplantation.
Animals were deeply anesthetized with a 1: 1 mixture of
Ketamine ( 100 mg/kg) and X y lazine (20 mg/kg) and mounted
onto a stereotaxic apparatus (ASI Instrument, USA). For
transplantation, approximately 105 cells HNSCs were suspended in 10 µl PBS, and slowly injected into the right lateral
ventricle of each mouse using a 25 µl Hamilton gastight
syringe (Hamilton, Reno, Nev., USA) with a 22-gauge beveled needle attached. The tip was held in place for 3 min
during delivery and left in place for another 3 min after each
injection. Intra-ventricular injection minimizes disruption of
brain tissue and may leverage endogenous signals (eg.
chemokines released by microglia in response to damage)
that might affect stem cell migration. In reference to the
bregma, the coordinates used for implantation were as follows: anterior posterior (A/P)-0.6 mm; medial lateral (M/L)
+1.0 mm; dorsal/ventral (D/V) +2.4 mm. No immune suppression was utilized and all efforts were made to minimize
the number of animals used and their suffering by observation
of maintained body weight and also by monitoring incisions
for swelling and proper healing of the incision site.
Protein Isolation and Western Blot Analysis.
Western blot analysis was performed to analyze effect of
( +)-phenserine on the relative APP and GFAP protein expression in APP23 and control mice. Dissected tissues from the
cortex and the hippocampus of (+)-phenserine and saline
treated animals were homogenized in ice-cold lysis buffer
containing 1% NP40, 150 mM NaCl, 50 mM Tris (pH 8.0),
and 1x protease inhibitor cocktail (Roche Diagnostics, Indianapolis, Ind.). The homogenates were centrifuged and
washed twice at 12,000x g for 10 min at 4 ° C. and the supernatants were used for protein quantification by the Bradford
method using Bio-Rad Protein Assay Dye Reagent (Bio-Rad,
Hercules, Calif.). Samples were denatured in a sample buffer
(Invitrogen, Carlsbad, Calif.) for 10 min at 70° C. Fifteen µg
of protein was loaded per well and proteins separated under
non-reducing conditions on NuPAGE 4-12% Novex Bis-Tris
gels (Invitrogen) for 60 min at 200 V, and then blotted onto
PVDF membranes (Bio-Rad) for 120 min at 30 V. For the
detection of APP and GFAP protein, membranes were
blocked in phosphate buffered saline, pH 7.4, and 0.05%
Tween-20 (PBS-T), with 5%non-fatdriedmilkand thereafter
incubated with mouse monoclonal anti-Alzheimer precursor
protein (22Cl 1) A4 antibody (1: 1000, Chemicon, Temecula,
Calif.) and rabbit anti-GFAP antibody (1: 1000, Promega,
Madison, Wis.) in PBS-T containing 1% non-fat dried milk
over night at 4° C. To standardize the amount of protein
loaded on to each gel, the polyclonal rabbit anti-B-actin antibody (1:1000, Cell Signaling Technology, Danvers, Mass.)
was used. The membranes were washed three times for 15
min in PBS-T and then incubated with secondary horseradish
peroxidase-conjugated antibodies (anti-mouse IgG and anti-

rabbit IgG, Jackson Immunoresearch Laboratories Inc, West
Grove, Pa.) at RT for 1 hr. Three final washes of 15 min in
duration each were performed. Signals were visualized by
incubation of the membranes in ECL Plus reagents (Amersham Biosciences, Buckinghamshire, UK), exposed to Hyper
Performance Chemiluminescence film (Amersham) and
developed according to standard procedures. The films were
scanned and the optical density of each specific band relative
to ~-actin, was analyzed by the public domain NIH Image J
software (version 1.33u) and expressed in means±SD from
experiments performed in triplicate.
Real Time RT-PCRAnalysis.
Total RNA from hippocampal and cortical tissues from
each animal treated with either (+)-phenserine or saline was
isolated with Trizol reagent (Invitrogen) according to the
manufacturer's protocol. One µg of the total RNA was transcribed into cDNA with reagents from the iScript cDNA
Synthesis Kit (Bio-Rad). Complete reaction mixture was prepared according to kit instructions and incubated at 42° C. for
30 min, 85° C. for 5 min and then cooled. Relative quantification with Real-time PCR was determined using the MyiQ
Real-Time PCR Detection System Software (Bio-Rad), and
reactions were performed in a thermal iCycler using the BioRad MyiQ IQ SYBR Green Supermix (Bio-Rad) according to
the following conditions; denaturation of cDNA for 5 min at
94° C.; amplification (40 cycles) for 30 sec at 94° C., annealing at 56° C. for 30 sec, and extension at 72° C. for 30 sec,
with a final extension at 72° C. for 5 min. The authenticity of
the PCR products was verified by melt-curve analysis at 55°
C. to 95° C. for 10 sec and cooling for 5 min at 20° C. The
primers used in this experiment were: APP (forward)
5'-GAGACACCTGGGGATGAGAA-3' (SEQ ID NO: 1,
APP (reverse) 5'-CTTGACGTTCTGCCTCTTCC-3' (SEQ
ID NO: 2, ~-actin (forward) 5'-CACACTGTGCCCATCTACG-3' (SEQ ID NO: 3, ~-actin (reverse) 5'-CCATCTCTTGCTCGAAGTCC-3' (SEQ ID NO: 4). The PCR efficiencies of the PCR reactions were evaluated from dilution series
of cDNA in real-time PCR. Threshold cycle (Ct) values were
used to plot a standard curve in which Ct decreased in linear
proportion to the log of the template copy number. A comparative Ct method was then utilized to determine relative
expression ratios of APP and ~-actin mRNA in samples.
Flourescent Immunohistochemistry.
Free floating coronal brain sections (20 µm) were washed
briefly in PBS, denatured with IM HCl for 20 min and neutralized with PBS for 30 min at room temperature (RT), in
order to increase the accessibility of the anti-BrdU antibody
to the BrdU incorporated in the cell nuclei. The sections were
then blocked in PBS containing 0.25% TritonX-100 and 3%
Normal Donkey Serum for 1 hr and incubated with sheep
polyclonal anti-BrdU (1:1000, Abeam, Cambridge, Mass.)
and mouse IgG2b anti-human ~III-Tubulin, clone SDL3D10
(1 :2000, Sigma), or rabbit IgG anti-human Glial Fibrillary
Acidic Protein (GFAP 1:500, Sigma) diluted in PBS containing 0.25% TritonX-100 and with 3% Normal Donkey Serum
overnight at 4 ° C. After rinsing in PBS-T, sections were
incubated with corresponding secondary antibodies (1:500)
conjugated with fluorescein (FITC) or rhodamine (TRITC)
(Jackson IR Laboratories, Inc.) for 2 hr at RT. After a final
wash in PBS-T, sections were mounted and cover slipped
with Vectashield with DAPI (Vector Laboratories, Inc., Burlingame, Calif.) for fluorescent microscopic observation.
Microscopy and Analysis of Differentiation.
Cell migration and differentiation in transplanted mice
(n=6-7 mice in each group) were quantified by unbiased
bilateral counts of number of BrdU positive cells expressing
either the neuronal marker, ~III-Tubulin, or the glial marker,
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GFAP, in the molecular and granule layers ofhippocampal
CAI, CA2 and dentate gyrus, and motor and sensory regions
of the cerebral cortex using a Leica DMRB fluorescent microscope at 400x magnification. Microscopic images were taken
with anAxiocam digital camera (Carl Zeiss) mounted on the
DMRB and processed using the QIMAGING with Q Capture
software (Qimaging Corporation).An average of 4-6 sections
were counted for each animal. The number of transplanted
cells counted in each section were averaged for each side so
that the final numbers represented the mean neuron or astrocyte number per sampling area.
Data and Statistical Analysis.
Data are presented as mean±SEM of different experiments
and differences between groups were analyzed with a twotailed Student's t-test. A simple linear regression test (GraphPad PRISM 3.0) was used to evaluate possible correlations.
Results
Reduced APP protein expresion following ( +)-phenserine
treatment
To investigate the effects of (+)-phenserine on APP protein
expression, Western blot analysis was performed on cortical
and hippocampal tissues fromAPP23 mice treated with either
( +)-phenserine (25 mg/kg, i.p. /day for 14 days) or saline. In
agreement with our previous findings, APP23 mice showed
significantly (p<0.05) higher levels of APP (-2-fold) compared to that of controls (FIG. 1). Following (+)-phenserine
treatment, a significant decrease (-3-fold) in APP protein
expression was observed in the hippocampus of APP23 mice
(p<0.01) compared to saline treated mice (FIG. 1). No significant change in APP protein expression was observed
between (+)-phenserine treated and saline treated wild-type
mice (FIG. 1). Although APP protein expression was also
reduced in the cerebral cortices ofAPP23 and wild-type mice
after (+)-phenserine treatment, these reductions did not reach
statistical significance (p>0.05, data not shown).
Reduced GFAP protein expression following (+)phenserine treatment
Previous studies have reported that APP overexpression in
APP23 mice is also associated with marked gliogenesis in the
brains of these mice (Sturchler-Pierrat and Staufenbiel,
2000). Therefore, we also measured GFAP (glial cell marker)
expression in these mice and investigated whether treatment
with (+)-phenserine could alter expression levels. We
observed that APP23 mice had significantly (p<0.05) higher
(-2.5-fold) GFAP protein expressed in the hippocampus
compared to that of wild-type mice. Following (+)phenserine treatment (25 mg/kg, i.p. /day for 14 days), GFAP
expression was significantly (p<0.05) reduced (-1.5-fold) in
APP23 mice (FIG. 1). No significant changes were observed
between (+)-phenserine treated and saline treated wild-type
mice (FIG. 1). GFAP protein expression in the cerebral cortices of APP23 and wild-type mice was similar and no significant change was observed after (+)-phenserine treatment
(data not shown).
Effect of (+)-phenserine on APP Gene Expression in
APP23 Mice
To investigate whether the (+)-phenserine-induced reduction of APP protein expression in APP23 mice was mediated
at the transcriptional level, quantitative real-time PCR analysis was performed on cortical and hippocampal tissues from
treated animals. However, no significant changes were
observed in APP gene expression following (+)-phenserine
treatment in both APP23 and wild-type mice (data not
shown), indicating that (+)-phenserine reduces APP levels by
post-transcriptional processing.

Effects of (+)-phenserine on Glial Differentiation ofTransplanted HNSCs in APP23 Mice
Six weeks after implantation, fluorescent double label
immunohistochemistry was employed to identify cells
derived from transplanted HNSCs (BrdU-labeled) and to
examine their differentiation into either neural or glial cells.
Also, we sought to determine whether the (+)-phenserineinduced effects on APP could influence the differentiation
fate of transplanted HNSCs. Transplanted HNSCs survived in
vivo and an extensive number of cells exhibiting characteristic astroglial morphologies, and co-expressing BrdU with the
astrocytic marker for human GFAP (BrdU+/GFAP+) were
observed in the molecular and granule layers of the hippocampal CAI, CA2 (FIGS. 2-3), and the dentate gyrus (data not
shown). Typically, APP23 mice showed more pronounced
immunoreactivity for BrdU+/GFAP+ compared to controls.
The cells expressing BrdU+/GFAP+ in hippocampal regions
were counted and the results were expressed as the average
number ofBrdU+/GFAP+ cells per region for each treatment
group (FIG. 4A-C). APP23 mice showed significantly
(p<0.01) more BrdU+/GFAP+ double immuno-positive cells
compared to that of wild-type mice (FIG. 4A-C). Following
(+)-phenserine treatment, a marked reduction (ranging from
28% to 40%) in number of BrdU+/GFAP+ double immunopositive cells was observed in hippocampal regions ofAPP23
mice (FIG. 4A-C), indicating that (+)-phenserine could
reduce the glial differentiation caused by APP over-expression. No significant differences in the number of Brdu+;
GFAP+ double immuno-positive cells were observed in the
hippocampus of wild-type mice after (+)-phenserine treatment (FIG. 4A-C). There was a significant correlation
(p<0.05; linearregressionr=0.47) between number ofBrdu+;
GFAP+ double immuno-positive cells and APP protein
expression in the hippocampus of APP23 mice (FIG. 4D).
Effects of (+)-phenserine on Neuronal Differentiation of
Transplanted HNSCs in APP23 Transgenic Mice
Examination of neuronal differentiation of transplanted
HNSCs was also performed inAPP23 and wild-type mice that
were treated with (+)-phenserine or saline. The number of
cells co-expressing BrdU with the neuronal marker for human
~-III tubulin (BrdU+/~-III tubulin+) were counted in the
molecular and the granule layers of the hippocampal CAI and
CA2, the dentate gyrus, and in the pyramidal layers of the
somatosensory and the motor cortex. To exclude the possibility that measured neuronal immunoreactivity was also detecting non-neuronal and endogenous neurons in mouse that
were not derived from the transplanted HNSCs, we stained in
parallel experiments sections with the neuronal marker NeuN
and a human nuclear specific antibody. Similar results were
obtained for NeuN staining as with ~-III tubulin and BrdU,
thus verifying that the differentiated cells were of human
origin (data not shown).
HNSCs transplanted into APP23 and wild-type mice differentiated into ~-III tubulin immuno-positive cells. The
BrdU+/~-III tubulin+ cells within the CAI and the CA2 region
had large pyramidal morphologies (FIG. 5-6), whereas those
in the dentate granule layer displayed a small ovoid appearance typical for dentate granule neurons (data not shown). In
the somatosensory and motor cortical regions, BrdU+/~-III
tubulin+ cells exhibited both pyramidal and non-pyramidal
morphologies (data not shown).
We anticipated a reduced neuronal differentiation of transplanted HNSCs in saline treatedAPP23 mice, based on earlier
findings in vitro where more glial differentiation of HNSCs
was observed after treatment with sAPP (Kwak et al., 2006).
Fewer BrdU+/~-III tubulin+ double immuno-positive cells
were detected in the motor and somatosensory cortex of
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APP23 mice in comparison to wild-type mice (FIG. 7D-E),
whereas no significant difference in the number ofBrdU+/~
III tubulin+ double immuno-positive cells was observed in the
hippocampal regions of APP23 mice compared to wild-type
mice (FIG. 7A-C). Interestingly, we observed a significant
increase (ranging from 32% to 112%) in the number of
BrdU+/~-III tubulin+ double immuno-positive cells in the
hippocampal CAI and CA2 (p<0.0001), and the motor and
the somatosensory cortex (p<0.05) of APP 23 mice after
( +)-phenserine treatment compared to the number of cells
found in APP23 treated with saline (FIG. 7A-B, D-E). A
significant (p<0.05) increase (40%) in the number of BrdU+I
~-III tubulin+ cells was observed only in the CAI hippocampal region of wild-type mice treated with (+)-phenserine
(FIG. 7A).
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 4
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 1
gagacacctg gggatgagaa

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 2
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 2
cttgacgttc tgcctcttcc

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 3
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 3
cacactgtgc ccatctacg

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 4
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 4
ccatctcttg ctcgaagtcc

20
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The invention claimed is:
1. A method of biasing implanted neural stem cells away
from differentiation into glial cells, said method comprising
administering to a patient in need thereof human neural stem
cells to said patient at a site of transplantation, said site of
transplantation being in the brain of said patient; and administering a regimen of (+) phenserine, wherein said (+)
phenserine is administered according to a regimen such that
the site of transplantation comprises an average soluble ~APP
concentration of about 0.5 to about 40 nanograms of soluble
~APP per milliliter of tissue or cerebrospinal fluid.
2. The method of claim 1, wherein the human neural stem
cells are administered by injecting the human neural stem
cells with a syringe, inserting the human neural stem cells
with a catheter or surgically implanting the human neural
stem cells.
3. The method of claim 2 wherein the human neural stem
cells are injected with a syringe into a brain cavity that is
fluidly-connected to a target area of neurological deficit.
4. The method of claim 2 wherein the human neural stem
cells are inserted with a catheter into a brain cavity that is
fluidly-connected to a target area of neurological deficit.
5. The method of claim 2 wherein the human neural stem
cells are surgically implanted into a brain cavity that is fluidly-connected to a target area of neurological deficit.
6. The method of claim 1, wherein said ( +) phenserine is
administered according to a regimen such that an average
~APP concentration of about 1 to 10 nano grams/ml of tissue
or cerebrospinal fluid is maintained over a period of at least
one day, two days, one week, two weeks, one month, two
months, three months, four months, five months, six months
or one year.

* * * * *

12

10

15

20

25

30

